Now, Bloom Science has said it plans to study BL-001 for the treatment of Dravet syndrome and amyotrophic lateral sclerosis (ALS) as well as other developmental and epileptic encephalopathies. It also ...

Praxis' epilepsy pipeline takes center stage after Ulixacaltamide's Phase 3 futility. Key trials for vormatrigine and ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

and the initiation of our Emerald registrational study of relutrigine in developmental epilepsies and encephalopathies (DEEs) by mid-year 2025. We maintain a robust financial position that supports ...

and the initiation of our EMERALD registrational study of relutrigine in developmental epilepsies and encephalopathies (DEEs) by mid-year 2025. We maintain a robust financial position that supports ...

While Australian researchers are paving the way in epilepsy care, findings show the significant burden on carers and parents with children living with severe epilepsies. Professor Ingrid Scheffer AO, ...

The Independent Data Monitoring Committee overseeing the interim analysis of Study 1 of the Essential3 program has provided Praxis with the ...

Praxis Precision Medicines, Inc.’s PRAX share price has dipped by 40.64%, which has investors questioning if this is right ...

A farm-raised deer in Eau Claire County tested positive for chronic wasting disease according to the Wisconsin Department of Natural Resources on Tuesday. The DNR was recently notified by the ...

Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children, including seizures, intellectual disability ...